First, the impact of a single administration of DCs on differences in the percentage of the myeloid cell population (CD11b+) in the tumor-draining lymph nodes on the 3rd, 5th, and 7th days using flow cytometry was assessed (Figure 7(a)). The gene discussed is ITGAM; the disease is neoplasm.